Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecBiohitOrionModulight

Latest content

ShowingAll content types

Faron’s anticipated opening in solid tumors

Analyst Comment 2026-01-28 07:28 by Antti Siltanen
Faron Pharmaceuticals

We take advantage of Biohit's January sale

Research 2026-01-16 08:32 by Antti Siltanen
Biohit

Orion: Nubeqa – oemotståndlig framgång

Research 2026-01-15 06:00 by Antti Siltanen
Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Stark guidning från Orion för 2026

Analyst Comment 2026-01-14 08:24 by Antti Siltanen
Orion

Orions ODM-212 går vidare till fortsatta studier

Analyst Comment 2026-01-09 06:26 by Antti Siltanen
Orion

Herantis: Biomarker analysis completed successful Phase I

Research 2026-01-09 10:01 by Antti Siltanen
Herantis Pharma

Herantis' latest analysis reveals HER-096's activity in central nervous system

Analyst Comment 2026-01-08 08:44 by Antti Siltanen
Herantis Pharma

Nexstim: A solid end to a record year

Research 2026-01-05 09:27 by Antti Siltanen
Nexstim

Herantis Pharma Extensive Report: Aiming for preliminary efficacy studies

Extensive research 2025-12-22 11:40 by Antti Siltanen
Herantis Pharma

Another welfare services country is piloting Nightingale's technology

Analyst Comment 2025-12-18 18:54 by Antti Luiro, Antti Siltanen
Nightingale Health
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.